CN112274513B - 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法 - Google Patents

含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法 Download PDF

Info

Publication number
CN112274513B
CN112274513B CN202011573509.7A CN202011573509A CN112274513B CN 112274513 B CN112274513 B CN 112274513B CN 202011573509 A CN202011573509 A CN 202011573509A CN 112274513 B CN112274513 B CN 112274513B
Authority
CN
China
Prior art keywords
pyrroloquinoline quinone
capsule
pharmaceutically acceptable
salt nonahydrate
trilithium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011573509.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN112274513A (zh
Inventor
张寰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Raising Pharmaceutical Co Ltd
Original Assignee
Shanghai Ri Xin Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Ri Xin Biotechnology Co ltd filed Critical Shanghai Ri Xin Biotechnology Co ltd
Priority to CN202011573509.7A priority Critical patent/CN112274513B/zh
Publication of CN112274513A publication Critical patent/CN112274513A/zh
Application granted granted Critical
Publication of CN112274513B publication Critical patent/CN112274513B/zh
Priority to PCT/CN2021/138255 priority patent/WO2022143168A1/zh
Priority to EP21913909.4A priority patent/EP4268821A4/en
Priority to JP2023539383A priority patent/JP7729639B2/ja
Priority to US18/269,783 priority patent/US20240058323A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202011573509.7A 2020-12-28 2020-12-28 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法 Active CN112274513B (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202011573509.7A CN112274513B (zh) 2020-12-28 2020-12-28 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法
PCT/CN2021/138255 WO2022143168A1 (zh) 2020-12-28 2021-12-15 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法
EP21913909.4A EP4268821A4 (en) 2020-12-28 2021-12-15 PHARMACEUTICAL COMPOSITION CONTAINING PYRROLOQUINOLINEQUINONETRILITHIUM SALT NONHYDRATE COMPOUND, CAPSULE AND MANUFACTURING PROCESS THEREOF
JP2023539383A JP7729639B2 (ja) 2020-12-28 2021-12-15 ピロロキノリンキノントリリチウム塩九水和物化合物を含む医薬組成物、カプセル剤およびその製造方法
US18/269,783 US20240058323A1 (en) 2020-12-28 2021-12-15 Pharmaceutical composition containing pyrroloquinoline quinone trilithium salt nonahydrate compound, capsule, and preparation method therefor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011573509.7A CN112274513B (zh) 2020-12-28 2020-12-28 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法

Publications (2)

Publication Number Publication Date
CN112274513A CN112274513A (zh) 2021-01-29
CN112274513B true CN112274513B (zh) 2021-03-26

Family

ID=74426482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011573509.7A Active CN112274513B (zh) 2020-12-28 2020-12-28 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法

Country Status (5)

Country Link
US (1) US20240058323A1 (cg-RX-API-DMAC10.html)
EP (1) EP4268821A4 (cg-RX-API-DMAC10.html)
JP (1) JP7729639B2 (cg-RX-API-DMAC10.html)
CN (1) CN112274513B (cg-RX-API-DMAC10.html)
WO (1) WO2022143168A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112274513B (zh) * 2020-12-28 2021-03-26 上海日馨生物科技有限公司 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103351387A (zh) * 2013-07-01 2013-10-16 上海日馨生物科技有限公司 吡咯喹啉醌锂盐晶体及其制备方法和应用
CN105189501A (zh) * 2013-04-26 2015-12-23 三菱瓦斯化学株式会社 黄色系还原型吡咯喹啉醌结晶及其制造方法、以及食品、医药品、凝胶、组合物和组合物的制造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63215628A (ja) * 1987-03-03 1988-09-08 Sogo Yatsukou Kk グリオキサラ−ゼｉ阻害剤
US5039699A (en) * 1989-03-27 1991-08-13 Lederle (Japan), Ltd. Anti-peptic ulcer agent
KR20070057218A (ko) * 2004-08-30 2007-06-04 가부시키가이샤 가네카 미토콘드리아 활성화제
CN101851234A (zh) * 2009-04-03 2010-10-06 上海日馨生物科技有限公司 吡咯喹啉醌锂盐衍生物及其制备方法
JP5636671B2 (ja) * 2009-12-17 2014-12-10 三菱瓦斯化学株式会社 ピロロキノリンキノンＬｉ塩の製造方法
JP6160621B2 (ja) * 2012-08-17 2017-07-12 三菱瓦斯化学株式会社 ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物
JP6439503B2 (ja) * 2014-03-13 2018-12-19 大正製薬株式会社 固形製剤
CN112274513B (zh) * 2020-12-28 2021-03-26 上海日馨生物科技有限公司 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189501A (zh) * 2013-04-26 2015-12-23 三菱瓦斯化学株式会社 黄色系还原型吡咯喹啉醌结晶及其制造方法、以及食品、医药品、凝胶、组合物和组合物的制造方法
CN103351387A (zh) * 2013-07-01 2013-10-16 上海日馨生物科技有限公司 吡咯喹啉醌锂盐晶体及其制备方法和应用

Also Published As

Publication number Publication date
JP2024500545A (ja) 2024-01-09
US20240058323A1 (en) 2024-02-22
EP4268821A4 (en) 2024-12-11
CN112274513A (zh) 2021-01-29
EP4268821A1 (en) 2023-11-01
WO2022143168A1 (zh) 2022-07-07
JP7729639B2 (ja) 2025-08-26

Similar Documents

Publication Publication Date Title
TWI778983B (zh) 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JP5632367B2 (ja) Ｂｉｂｗ２９９２を含有する固形医薬製剤
JP5461179B2 (ja) セルロース系微小核粒子及びその製造方法
JP7232284B2 (ja) 薬物を含有する即放性錠剤及び錠剤の形成プロセス
Lou et al. Development of a mini-tablet of co-grinded prednisone–neusilin complex for pediatric use
JP2007031451A (ja) ラソフォキシフェン錠剤およびそのコーティング
WO2016188472A1 (zh) Mek抑制剂的药物组合物及其制备方法
CN111278431A (zh) 普利多匹定的高浓度剂型
CN102633777A (zh) 达比加群酯2-酮戊二酸盐及其制备方法和应用
JP2023156269A (ja) テネリグリプチン含有医薬組成物
CN112274513A (zh) 含有吡咯喹啉醌三锂盐九水化合物的药物组合物、胶囊剂及其制备方法
CN113209036B (zh) 一种阿齐沙坦片及其制备方法和应用
JP7264711B2 (ja) レベチラセタム含有医薬組成物の製造方法
JP2015071542A (ja) 固体分散体の製造方法
CN120022270A (zh) 一种吲哚布芬缓释制剂及其制备方法和应用
CN106860408B (zh) 一种格列美脲片
JP4596586B2 (ja) トレハロース粒子
US20230346763A1 (en) Method for preparing solid formulation of pimavanserin
Burra et al. Enhancement of solubility and dissolution rate of Frusemide through liquisolid technique
CN119367359B (zh) 一种阿利沙坦酯组合物及其制备方法
Panda et al. Bioavailability Enhancement and Polymorphic Stabilization of One BCS Class IV Metastable Drug Through Novel Formulation Approach
JP7854233B2 (ja) アピキサバン含有組成物、アピキサバン含有固形製剤、及びアピキサバン含有固形製剤の製造方法
CN104337783B (zh) 一种卡培他滨片剂及其制备方法
JP5931219B2 (ja) アリピプラゾールを含む経口固形製剤、及びアリピプラゾールを含む経口固形製剤の製造方法
JP2021098671A (ja) レベチラセタム含有医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: No.1, Lane 215, Amber Road, Pudong New Area, Shanghai, 201321

Patentee after: Shanghai Rixin Pharmaceutical Technology Co.,Ltd.

Address before: No.1, Lane 215, Amber Road, Pudong New Area, Shanghai, 201321

Patentee before: Shanghai Ri Xin Biotechnology Co.,Ltd.

CP01 Change in the name or title of a patent holder